House Committee Calls for CMS Action on Biosimilars
Tony Hagen | The Center for Biosimilars
“Alex Brill, founder of economic consulting firm Matrix Global Advisors and a resident fellow at the American Enterprise Institute, discussed a solution that Congress or the administration could approve that aligns the incentives of physicians and taxpayers to mitigate the rising costs of biologic spending.
‘One of the ways to align these incentives would be for CMS, in particular the Center for Medicare & Medicaid Innovation, to launch a demonstration project, a shared savings program in Medicare Part B for biosimilars. This would reward physicians for increasing their utilization of biosimilars, which would both create that incentive for physicians and align that incentive with the desire of taxpayers to lower overall costs in the biologic spend category,’ he said.”